D. Western Therapeutics Institute, Inc. (TYO:4576)

Japan · Delayed Price · Currency is JPY

80.00

0.00 (0.00%)

Aug 6, 2026, 1:34 PM JST

-28.57% (1Y)

Market Cap	4.60B -10.9%
Revenue (ttm)	305.97M -34.0%
Net Income	-652.71M
EPS	-12.92
Shares Out	57.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,600
Open	80.00
Previous Close	80.00
Day's Range	79.00 - 81.00
52-Week Range	66.00 - 181.00
Beta	-0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 19

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4576

Full Company Profile

Financial Performance

In 2025, TYO:4576's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.

Financial Statements